Platinum-based agents, such as cisplatin, form the mainstay of currently used chemotherapeutic regimens for several malignancies ([@bib4]; [@bib15]). Notwithstanding the immense therapeutic success associated with partial responses or disease stabilisation, the main limitations to the clinical usefulness of cisplatin are the incidence of chemoresistance and its adverse side effects ([@bib15]). Frequently, patients with relapsed or recurrent disease present resistance to cisplatin ([@bib23]; [@bib9]) and the debilitating side effects such as progressive irreversible ototoxicity ([@bib30]) characterise further major limitations to cisplatin dose escalation. Cisplatin causes a bilateral, symmetric high-frequency hearing loss, often accompanied by tinnitus, as the dose or number of treatments increase; this permanent impairment is responsible for communicative disorders harming further the quality of life of cancer patients ([@bib41]; [@bib30]; [@bib13]). Research addressed to overcome cisplatin limitations has been focused on the development, as an adjuvant therapy, of safe molecules able to counteract chemotherapy-associated organ toxicity and to promote tumour toxicity and chemosensitisation. It is now widely accepted that: (a) cisplatin apoptogenicity depends on the formation of ROS and that apoptogenic oxidative stress is the crucial mechanism of both cisplatin-induced cancer cell death ([@bib5]) and damage to vulnerable normal cells ([@bib55]); (b) one of the major systems used by both normal and cancerous cells to counteract oxidative insult is the NF-E2 p45-related factor 2 (Nrf-2) transcriptionally regulated program ([@bib20]; [@bib55]; [@bib47]); (c) JAK-STAT (Janus kinase-STAT) pathway contributes to tumour cell proliferation and survival, tumour invasion and angiogenesis ([@bib25]; [@bib57]). Thus, the identification of adjuvant redox therapeutics targeting Nrf-2 and STAT3 constitutes the most rational approach for prevention of chemoresistance and of chemotherapy-associated organ toxicity.

As adjuvant chemotherapeutics, selective pro-oxidant redox intervention that substantially increases cellular ROS and modulates specific redox-sensitive targets can be achieved using small-molecule electrophiles containing a Michael acceptor pharmacophore contained in natural products ([@bib55]). Indeed, nutraceuticals have gained notable interest as viable candidates and the polyphenol curcumin has been studied for the past few decades, with encouraging outcomes, for the antinflammatory, antioxidant, antiproliferative and preventive actions ([@bib2]; [@bib52]; [@bib50]; [@bib17]; [@bib58]). Curcumin is able to influence multiple intracellular pathways and its pro-oxidant or antioxidant effects depend, however, on the concentration of the compound as recently demonstrated by our group in cisplatin-induced ototoxicity ([@bib13]). Curcumin is considered a potential hormetin, a coinducer at low doses of heat-shock protein and a direct inducer of heme oxygenase-1 (HO-1), a well-known marker of intracellular stress defence system, and at high doses a cellular growth inhibitor ([@bib6]; [@bib10]).

On such basis, this research was conceived to explore the pro-oxidant potential of curcumin as a chemotherapeutic adjuvant targeting *in vitro* the transcription factors involved in tumour progression and cisplatin resistance, STAT3 and Nrf-2, and the antioxidant curcumin activity by analysing *in vivo* the protective molecular changes in a model of chemotherapy organ toxicity to further investigate the role of the Nrf-2/HO-1 defence system in healthy cells undergoing a stressful condition. Namely, the combinatorial strategy was tested in: (1) the head and neck squamous cell carcinoma (HNSCC) that represents a significant clinical problem and unsatisfactory long-term survival of patients ([@bib7]) and (2) the *in vivo* model of cisplatin-induced ototoxicity, a well-known adverse effect frequently associated with head and neck cancer treatments. Finally, to distinguish between the pro-oxidant and antioxidant curcumin effects and to mimic a possible treatment dosage to be reached in systemic tissues, we used, both in *in vitro* and *in vivo* experiments, different curcumin doses considering that the therapeutic use of curcumin has been limited owing to its poor bioabsorption ([@bib28]; [@bib40]).

Materials and methods
=====================

Chemicals
---------

Common laboratory chemicals were from Sigma-Aldrich (Milan, Italy), unless differently stated. Antibodies used are listed below in methods where appropriate.

Refer to [Supplementary Materials](#sup1){ref-type="supplementary-material"} for details of experimental procedures.

*In vitro* experiments
----------------------

### Cell line

We used PE/CA-PJ15 human oral squamous carcinoma cell line (European Collection of Cell Cultures) cultured in Iscove\'s modified Dulbecco\'s modified Eagle\'s medium (DMEM) (IMDM) supplemented with 10% foetal bovine serum (Biochrom, Berlin, Germany), 1% penicillin/streptomycin (10 000 U ml^−1^/10 000 *μ*g ml^−1^; Biochrom) and 1% of [L]{.smallcaps}-glutamine 200 m[M]{.smallcaps} (Biochrom) at 37 °C in an atmosphere of 95% oxygen and 5% CO~2~.

### Drug administration

Curcumin (high purity; code: C7727) was dissolved in 0.5% dimethylsulphoxide (DMSO; code: 34869) and EtOH and sterile H~2~O (1 : 1) and the range of administered doses was 0.5, 1.0, 3.37 and 6.75 *μ*[M]{.smallcaps}. Cisplatin (CDDP; code: P4394), dissolved in sterile saline, was administered at a dose of 1.56 *μ*[M]{.smallcaps}. PE/CA-PJ15 cells were tested in two experimental conditions detailed in [Supplementary Materials](#sup1){ref-type="supplementary-material"}. No significant differences were observed between control (not treated) and control vehicle cells (data not shown). Cisplatin, curcumin and DMSO were purchased from Sigma-Aldrich.

### Cell survival

To evaluate the toxic effect of curcumin, cisplatin and the combined drug exposure, 1.0 × 10^4^ cells per well were fixed with 4% paraformaldehyde for 15 min, washed two times in phosphate-buffered saline and then incubated in a solution containing DAPI (4\',6-diamidino-2-phenylindole; 1 : 1000 in phosphate-buffered saline 0.1 [M]{.smallcaps}) and Triton (TX, 0.1% in phosphate-buffered saline 0.1 [M]{.smallcaps}) for 10 min, light protected and at room temperature. Condensed cell nuclei were identified by DAPI labelling.

### pSTAT3 and Nrf-2 immunofluorescence

pSTAT3 and Nrf-2 immunofluorescence were performed using primary antibodies such as rabbit anti-phospho-STAT3 (Tyr705) (Cell Signalling Technology, Boston, MA, USA) and mouse anti-Nrf-2 (Abcam, Cambidge, UK), respectively. The secondary antibodies for pSTAT3 and Nrf-2 were goat anti-rabbit 488 (Alexa Fluor) and donkey anti-mouse 546 (Alexa Fluor), respectively. DAPI counterstained the cell nuclei. Images of pSTAT3- and Nrf-2-immunolabelled specimens (40 ×) were taken by the confocal laser scanning microscope (TCS-SP2; Leica Microsystem GmbH, Wezlar, Germany). Immunofluorescence was performed 24, 48 and 72 h after treatment. However, given that no significant differences were observed among the three time points, only the results at 24 h are discussed.

### TUNEL assay

Apoptosis was evaluated in PE-CA/PJ15 cultures with the APO-BrdU TUNEL Assay Kit (Invitrogen, Carlsbad, CA, USA) 48 h after treatment, according to the manufacturer\'s instructions, as described previously ([@bib39]).

### Western blot

PE/CA-PJ15 cells (2 × 10^6^) were trypsinised 48 h after drug treatment and protein concentration was measured using a Micro BCA Kit (Pierce, Rockford, IL, USA). Protein expression was evaluated and documented using UVItec Cambridge Alliance (Cambridge, UK). The experiments were repeated three times, and an interexperiment variability of \<10% was found.

*In vivo* experiments
---------------------

### Animals

Male adult Wistar rats (200--250 g, UCSC Laboratories, Rome, Italy) were used (25 animals, randomised and assigned to four experimental groups as detailed in [Supplementary Materials](#sup1){ref-type="supplementary-material"}). All efforts were made to minimise animal suffering and to reduce their number, in accordance with the European Community Council Directive of 24 November 1986 (86/609/EEC). All procedures were performed in compliance with the Laboratory of Animal Care and Use Committee of the Catholic University, School of Medicine of Rome and were approved by the Italian Department of Health (*Ministero della Salute*).

### Drug administration

As described previously ([@bib13]), curcumin, dissolved in DMSO, was administered intraperitoneally at three different doses (100, 200 and 400 mg kg^−1^ body weight). Curcumin solution was injected 1 h before cisplatin administration and once daily for the following 3 days. A single cisplatin dose of 16 mg kg^−1^ ([@bib13]) was delivered intraperitoneally at a rate of 8 ml h^−1^ with an infusion pump (Axon Instruments, Foster City, CA, USA) over 30 min. The animals were hyperhydrated with saline solution (subcutaneous injection, 15 ml daily) to limit cisplatin side effects.

### Auditory function evaluation

*Auditory brainstem responses*: We performed auditory brainstem response (ABR) recordings to identify the acoustic threshold of each animal for each group ([@bib12], [@bib13]). ABRs were measured at low (6 kHz), mid (12, 16 and 20 kHz) and high (24 and 32 kHz) frequencies. In all animals, ABRs were assessed bilaterally before treatment (day 0) to assure normal hearing and reassessed at all time points (3 and 5 days from treatment onset) to evaluate the effect of treatments on hearing. PC-controlled TDT System 3 (Tucker-Davis Technologies, Alachua, FL, USA) data acquisition system with real-time digital signal processing was used for ABR recording and auditory stimulus generation (tone bursts of pure tones from 6 to 32 kHz, 1 ms rise/fall time, 10 ms total duration, 20/s repetition rate). Threshold value was defined as the lowest stimulus level that yielded a repeatable waveform-based onset.

*Distortion product otoacoustic emissions*: To determine treatment effect on OHC function, distortion product otoacoustic emissions (DPOAEs) were measured unilaterally using an otoacoustic emission system (Tucker-Davis Technologies, Alachua, FL, USA). Distortion product otoacoustic emissions were recorded before, and 3 and 5 days after the onset of treatment per second.

### Morphological analyses and cell viability

Rhodamine-phalloidin (Rh-Ph) staining was used to visualise the stereociliary arrays and cuticular plates of hair cells ([@bib13]), performed at day 5 in 5 cochleae per group. All morphologic observations were performed with the confocal laser scanning system.

### Nrf-2/HO-1 and pSTAT3 immunostainings

Immunostainings were performed at day 5 in cochlear cryosections to assess and quantify the endogenous antioxidant response to cisplatin-induced damage and to evaluate the effect of curcumin supplementation ([@bib12], [@bib14]). Five cochleae per group were used. Images were obtained with the confocal laser scanning system. We acquired confocal Z-stacks in series of 15--20 *μ*m thick to evaluate the real extent of the nuclear and/or cytoplasmatic HO-1, Nrf2 and pSTAT3 fluorescence of the organ of Corti and SGNs ([@bib14]). Control experiments (negative controls not shown) were performed by omitting the primary antibody during the processing of tissues randomly selected across experimental groups.

### Statistical analysis

Results are presented as means±s.e.m., and differences were assessed using analysis of variances (ANOVAs). *P*\<0.05 was considered significant.

Results
=======

*In vitro* experiments
----------------------

### Curcumin enhances cisplatin cytotoxicity in PE/CA-PJ15 cells

Tumour survival and growth of PE/CA-PJ15 cells were evaluated at 24, 48 and 72 h after treatment. Curcumin administration induced a cytotoxic effect in a dose-dependent manner (upper panel of [Figure 1](#fig1){ref-type="fig"}): (a) 0.5 *μ*[M]{.smallcaps} induced a slight cell loss that progressed over time to reach ∼20% of cell loss after 48 and 72 h of incubation, (b) 1.0 *μ*[M]{.smallcaps} showed a similar effect, ∼20% and 25% of cell loss at 48 and 72 h, respectively, (c) with 3.37 *μ*[M]{.smallcaps} the cytotoxic effect increased, causing ∼40% of cell loss at 72 h, (d) 6.75 *μ*[M]{.smallcaps} caused ∼60--70% of cell loss at 48 and 72 h, respectively ([Figure 1A](#fig1){ref-type="fig"}). Moreover, low doses of curcumin affected marginally tumour proliferation at the analysed time points ([Figure 1B](#fig1){ref-type="fig"}); whereas starting from curcumin doses of 3.37--6.75 *μ*[M]{.smallcaps}, cell proliferation was highly affected from 24 to 72 h ([Figure 1C--E](#fig1){ref-type="fig"}). The dose-dependent effects of curcumin on PE-CA/PJ15 were also shown by signs of cell death, nuclear fragmentation and swelling, by DAPI staining ([Figure 1F--J](#fig1){ref-type="fig"}). The effects of cisplatin monotherapy and of combined regimen (cisplatin+curcumin) on PE/CA-PJ15 cells are shown in [Figure 2](#fig2){ref-type="fig"} (upper panel), and indicate that cisplatin administration induced cell loss of ∼20% at 24 h, increasing in later time points of ∼55% and 60% after 48 and 72 h, respectively ([Figure 2A](#fig2){ref-type="fig"}). The adjuvant curcumin doses of 0.5 and 1.0 *μ*[M]{.smallcaps} determined cell loss of ∼30%, 40% and 60% at 24, 48 and 72 h, respectively ([Figure 2A](#fig2){ref-type="fig"}). This effect increased with the dose of 3.37 *μ*[M]{.smallcaps} causing ∼35%, 70% and 80% of cell death after 48 and 72 h, respectively ([Figure 2A](#fig2){ref-type="fig"}). A marked cytotoxicity was observed at the adjuvant highest curcumin dose of 6.75 *μ*[M]{.smallcaps}, causing cell loss of ∼55% after 24 h and of ∼70% and 90% after 48 and 72 h, respectively ([Figure 2A](#fig2){ref-type="fig"}). With regard to cell proliferation, cisplatin arrested tumour growth ([Figure 2B--E](#fig2){ref-type="fig"}), whereas the adjuvant high and medium curcumin doses decreased proliferation rate already at 24 h ([Figure 2C--E](#fig2){ref-type="fig"}). The adjuvant curcumin doses of 0.5 and 1.0 *μ*[M]{.smallcaps} did not modify the effect of cisplatin on cell proliferation ([Figure 2B](#fig2){ref-type="fig"}). In [Figure 2F--K](#fig2){ref-type="fig"}, images representative of DAPI staining illustrate the cytotoxic effects.

### Curcumin enhances apoptotic activation: TUNEL assay and Bax western blotting

The analysis of DNA fragmentation in PE/CA-PJ15 cells revealed low rates of apoptosis (\<5%) in control cultures ([Figures 1K, Q](#fig1){ref-type="fig"} and [2L, R](#fig2){ref-type="fig"}) and no significant differences were observed in cells exposed for 48 h to 0.5 or 1.0 *μ*M of curcumin ([Figure 1L and M](#fig1){ref-type="fig"}). However, a marked TUNEL labelling was observed after treatment with high and medium doses of curcumin, with an increase in the number of apoptotic-positive cells of ∼15% and 20%, respectively ([Figure 1N, O and Q](#fig1){ref-type="fig"}). These data were also supported by western blot analysis for Bax expression. Interestingly, proapoptotic expression of Bax increased markedly in cells treated with medium and high doses of curcumin with respect to lower dose treatments and control cells ([Figure 1P](#fig1){ref-type="fig"}). Cisplatin monotherapy induced the activation of apoptotic processes, with ∼20% of TUNEL-positive cells ([Figure 2M and R](#fig2){ref-type="fig"}). The adjuvant curcumin treatment caused an enhancement of apoptotic-positive cells in a dose-dependent manner: the highest effect was observed at 3.37 and 6.75 *μ*[M]{.smallcaps} doses, causing DNA fragmentation in ∼35--40% of cells ([Figure 2P--R](#fig2){ref-type="fig"}). Collectively, these results illustrate the dose-dependent proapoptotic effect of curcumin, both in the mono- and combinatorial chemotherapy.

### Curcumin inhibits pSTAT3 signalling

[Figure 3](#fig3){ref-type="fig"} shows pSTAT3 immunofluorescence data. Although in control specimens there was a clear pSTAT3 labelling in the nucleus and in the cytoplasm ([Figure 3A](#fig3){ref-type="fig"}), the fluorescence decreased progressively by increasing curcumin doses ([Figure 3C, E, G and I](#fig3){ref-type="fig"}). In cisplatin-treated cells, pSTAT3 labelling was evident in both the cytoplasm and nucleus ([Figure 3B](#fig3){ref-type="fig"}). In the combined treatment, there was a marked decrease in STAT3 phosphorylation, indicated by a change in fluorescence localisation, which remained confined inside the cytoplasm of cells ([Figure 3D, F, H and J](#fig3){ref-type="fig"}). This effect was more evident when medium and high doses of curcumin were used ([Figure 3H and J](#fig3){ref-type="fig"}), as illustrated by immunofluorescence optical density analysis ([Figure 3U](#fig3){ref-type="fig"}). Taken together, these results indicate that curcumin potentiates antineoplastic effect of cisplatin by acting on the inhibition of STAT3 phosphorylation: marked fluorescence intensity in the cytoplasm but absent in the nucleus indicated deficient pSTAT3 translocation.

### Curcumin combinatorial treatment inhibits Nrf-2 nuclear translocation

Immunofluorescence data revealed a slight Nrf-2 labelling in control condition ([Figure 3K](#fig3){ref-type="fig"}). PE/CA-PJ15 exposed to different doses of curcumin showed an increase in nuclear Nrf-2 fluorescence, in a dose-dependent manner ([Figure 3M, O, Q and S](#fig3){ref-type="fig"}). Immunofluorescence data of cisplatin monotherapy revealed a marked raise of Nrf-2 labelling, primarily cytoplasmic ([Figure 4L](#fig4){ref-type="fig"}). Interestingly, the adjuvant curcumin doses caused an increase in Nrf-2 activation that, however, remained restricted inside the cytoplasm, without translocation into the nucleus ([Figure 3N, P, R and T](#fig3){ref-type="fig"}). This effect was more evident at medium and high curcumin doses, as shown also by fluorescence quantification data ([Figure 3V](#fig3){ref-type="fig"}). Thus, these results indicate that, when administered in conjunction with cisplatin, curcumin treatment can counteract Nrf-2 activation and nuclear translocation and favours chemosensitisation.

*In vivo* experiments: cisplatin ototoxicity
--------------------------------------------

### Curcumin otoprotective effect on auditory function: ABR and DPOAEs

ABRs were recorded in all animals before (day 0), and 3 and 5 days after drug treatment onset. Baseline ABR thresholds did not differ among the experimental groups, consistent with previous data ([@bib13]). The ABR data are expressed in terms of threshold shift that represents the difference between the pre- and post-treatment values of each animal for each group. Cisplatin administration induced a threshold elevation of ∼35--40 dB at days 3 and 5, respectively, as reported previously ([@bib13]) ([Figure 4A and B](#fig4){ref-type="fig"}). Treatment with curcumin 200 mg kg^−1^ decreased cisplatin ototoxicity of ∼20--25 dB at the same time points ([Figure 4A and B](#fig4){ref-type="fig"}). However, the lower dose of curcumin (100 mg kg^−1^) had no effect and the higher dose (400 mg kg^−1^) worsened, at day 5, the functional damage induced by cisplatin ([Figure 4A and B](#fig4){ref-type="fig"}). Furthermore, the effect of the combined treatment on OHC function was tested by DPOAEs in all animals. Sixteen kHz data (frequency most affected by cisplatin administration) show a progressive decrease in amplitude in the cisplatin group, spanning from high to low DPOAE levels ([Figure 4C and D](#fig4){ref-type="fig"}). The largest changes occurred at day 5. Curcumin treatment (200 mg kg^−1^) significantly attenuated the decrease of DPOAE amplitude both at days 3 and 5 ([Figure 4C and D](#fig4){ref-type="fig"}). However, both low (100 mg kg^−1^) and high (400 mg kg^−1^) doses of curcumin failed to protect OHC function ([Figure 4C and D](#fig4){ref-type="fig"}).

### Curcumin-protective effect in the organ of Corti: morphological analysis

[Figure 4](#fig4){ref-type="fig"} (lower panel) shows Rh-Ph staining and cochleogram of Ctrl, cisplatin and cisplatin+curcumin groups (200 and 400 mg kg^−1^). No difference was observed between cisplatin and cisplatin+curcumin 100 mg kg^−1^ groups (data not shown). Cisplatin administration induced mostly OHC loss, which was characterised by dark spots, phalangeal scars and disappearance of both cuticular plate and hair bundle in the middle and basal turns ([Figure 4F](#fig4){ref-type="fig"}). Also, OHC count showed ∼55% of hair cell survival in basal turn and ∼75% in middle turn in the cisplatin group as compared with Ctrl ([Figure 4I](#fig4){ref-type="fig"}). In the cisplatin+curcumin 200 mg kg^−1^ group, the survival reached ∼85% and 95% in the same regions of basal and middle turns, respectively. Values in cisplatin+curcumin 400 mg kg^−1^ group did not differ significantly from cisplatin group: cell survival of ∼70% in middle turn and ∼50% in basal region. No significant differences were observed in the apical turn among groups.

### Curcumin induces Nrf-2/HO-1 pathway activation

[Figures 5](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"} show representative Z-stack acquisitions of Nrf-2 (left panels) and HO-1 (right panels) immunostainings in high magnifications (100 ×) of the organ of Corti and of SGNs, respectively. In control specimens, Nrf-2 and HO-1 labelling was slightly displaced in the cytosol in OHCs ([Figure 5A and B](#fig5){ref-type="fig"}) and in SGNs ([Figure 6A and B](#fig6){ref-type="fig"}) as shown by the XZ cross-sections (boxes a~1~--a~3~ and b~1~--b~3~ in [Figures 5](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"}). In both organ of Corti and SGNs of cisplatin specimens, Nrf-2 ([Figures 5](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"}, boxes c~1~--c~3~) and HO-1 ([Figures 5](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"}, boxes d~1~--d~3~) labelling was mainly localised in the cytoplasm. No differences were observed with curcumin doses 100 and 400 mg kg^−1^ as compared with cisplatin specimens (images not shown). Treatment with curcumin 200 mg kg^−1^ induced nuclear translocation of Nrf-2, as clearly indicated by XZ cross-sections ([Figures 5](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"}, boxes e~1~--e~3~). In these specimens, high Nrf-2 fluorescence signal was detected not only in the cytoplasm but also in the nucleus, both in OHCs ([Figure 5E](#fig5){ref-type="fig"}) and in SGNs ([Figure 6E](#fig6){ref-type="fig"}). In parallel, in the same samples, we observed an overexpression of HO-1 both in the organ of Corti ([Figure 5F](#fig5){ref-type="fig"}) and in SGNs ([Figure 6F](#fig6){ref-type="fig"}), confined inside the cytoplasm (boxes f~1~--f~3~). Namely, the enhancement of Nrf-2 expression and its nuclear translocation, observed after curcumin administration, appears to reflect the upregulation HO-1 protein expression. Collectively, our data indicate that curcumin can activate, Nrf-2/HO-1 pathway, and potentiate this endogenous antioxidant defence mechanism against cisplatin ototoxicity.

### Curcumin does not influence STAT3 phosphorylation

In control samples, STAT3 labelling was faint and mainly localised inside the cytoplasm. Cisplatin treatment did not modify pSTAT3 fluorescence, which did not translocate into the nucleus. Also, curcumin treatment at all doses did not influence STAT3 phosphorylation, which remained confined inside the cytoplasm, with no differences compared with the other groups (images not shown). Taken together, these results indicate that in our model of cisplatin-induced ototoxicity *in vivo*, curcumin does not act by targeting pSTAT3 signalling.

Discussion
==========

Our results indicate that curcumin enhances cisplatin activity in HNSCC cells and provides protection from cisplatin side effects in the cochlea by targeting differently the transcription factors STAT3 and Nrf-2. Additionally, curcumin pro-oxidant effect in cancer cells and antioxidant action in normal cisplatin-stressed cells can both be achieved by relatively low doses.

Curcumin\'s effect was analysed in the *in vitro* model of the head and neck cancer, which often demonstrates significant resistance to cisplatin, acquired through repeated treatment cycles or as an inherent characteristic of the cancer ([@bib27]; [@bib1]). Curcumin, used as monotherapy at low doses (0.5 and 1.0 *μ*[M]{.smallcaps}), was able to induce a relatively modest antitumor effect (∼20% increase). Both the antiproliferative and cytotoxic effects increased with the medium dose (3.37 *μ*[M]{.smallcaps}) and were remarkably magnified at the highest dose (6.75 *μ*[M]{.smallcaps}) as shown in [Figure 1A--E](#fig1){ref-type="fig"}. The increasing proapoptotic activation was documented by the dose-dependent number of TUNEL-positive cells and increased Bax expression ([Figure 1P](#fig1){ref-type="fig"}). As an adjuvant to cisplatin chemotherapy, curcumin had an overall pro-oxidant activity: the antitumor effect was increased in a dose-dependent mode and the medium and high doses induced an intense cytotoxic and antiproliferative effect (∼4-folds higher than cisplatin alone) as documented by the analysis of effect magnitude and by increased apoptosis ([Figure 2E and L--R](#fig2){ref-type="fig"}). These findings are consistent with the literature with regard to curcumin antitumor efficacy when used as monotherapy or as an adjuvant *in vitro* ([@bib17]; [@bib1]; [@bib7]); however, translation to *in vivo* models and to clinical settings may pose some concerns with regard to poor bioavailability of curcumin ([@bib8]; [@bib21]). The low aqueous solubility and high degradation velocity of curcumin may indeed result in suboptimal blood concentrations to achieve the therapeutic effects ([@bib3]; [@bib37]); however, it can be remarked that a relevant antitumor effect *in vitro* was observed at the low/medium doses of curcumin that could be more easily reached *in vivo* to obtain decreased tumour volume as shown in a curcumin-treated xenograft ([@bib54]). In addition, the use of novel curcumin analogues with low toxicity and good bioabsorption ([@bib28]) or nanoparticle curcumin formulations ([@bib16]; [@bib37]; [@bib40]; [@bib42]) offer promising approaches to overcome bioavailability characteristics and enhance the therapeutic efficacy of cisplatin in head and neck cancer patients.

The main objective of this study was, however, to get insights into the molecular targets of curcumin at different doses and we found that both pSTAT3 and Nrf-2, expressed in the control cultures, were, respectively, down- and upregulated in a dose-dependent manner by curcumin monotherapy. Notably, the effect of the low doses (0.5 and 1.0 *μ*[M]{.smallcaps}) on pSTAT3 was remarkable and the labelling trend was not so dissimilar as compared with the medium and high doses. As compared with controls, cisplatin did not change the nuclear and cytoplasmic pSTAT3 level that was inhibited by curcumin in the combinatory treatments even at the dose of 0.5 *μ*[M]{.smallcaps} ([Figure 3](#fig3){ref-type="fig"}). Signal transducer and activator of transcription 3 has been shown to be constitutively expressed in HNSCC both *in vitro* and *in vivo* ([@bib18]; [@bib48]) and ∼82% of HNSCCs exhibit upregulation of STAT3 expression ([@bib34]), and enhanced STAT3 expression enhances HNSCC survival ([@bib32]). Overexpression of STAT3 induces tumours in nude mice ([@bib24]) and interruption of STAT3 signalling impedes cancer cell growth, enhances apoptosis in HNSCC ([@bib33]) and sensitivity to cisplatin *in vitro* HNSCCs ([@bib19]; [@bib38]; [@bib59]), underlying its potential as a therapeutic target in this cancer. Signal transducer and activator of transcriptions has central roles in cancer and inflammation and signalling by various STATs, particularly STAT3, is highly interconnected with nuclear factor-*κ*B (NF-*κ*B) signalling, recognised as a major pathway responsible for both inflammation-induced carcinogenesis and antitumour immunity ([@bib26]; [@bib44]; [@bib36]; [@bib54]; [@bib31]). It can be speculated that, in our *in vitro* experiments, curcumin might interfere with STAT3 signalling even at low doses either by reducing its nuclear translocation and downstream activation of a broad array of target genes ([@bib35]) or, possibly, by curcumin direct inhibition of NF-*κ*B activation that occurs mainly via I-κB kinase (IKK)-mediated phosphorylation of inhibitory molecules ([@bib52]; [@bib46]). Additionally, curcumin, by exerting its well-known anti-inflammatory effects, could hamper the possible cytokine-induced activation of the JAK-STAT pathway ([@bib29]), decreasing thus the level of cytoplasmic pSTAT3 and consequent decrease of its nuclear translocation as observed in our *in vitro* experiments (compare pSTAT3 cytoplasmic level of cisplatin treatment with the combined one in [Figure 3U](#fig3){ref-type="fig"}). Altogether, the STAT3 curcumin targeting may represent a reliable strategy to increase the HNSCC sensitivity to cisplatin and STAT3 expression may represent an effective biomarker for predicting the response to targeting therapy ([@bib28]; [@bib59]).

The effect of curcumin on the other molecular target Nrf-2 *in vitro* was consistent with the literature data ([@bib50]). Curcumin increased both cytoplasmic and nuclear Nrf-2 labelling in cancer cells, the increase was dose-dependent and the nuclear translocation reached the maximum level at 3.37 *μ*[M]{.smallcaps} curcumin dose. Cytoplasmic Nrf-2 was intense and its nuclear translocation was present in cisplatin-treated cells, but, interestingly, when curcumin was combined with cisplatin treatment, cytoplasmic Nrf-2 increased with curcumin increments and the nuclear translocation decreased. Nuclear Nrf-2 labelling was faint at a combined curcumin dose of 6.75 *μ*M. Again, curcumin effect was different, protranslocation in the monotherapy and translocation inhibitory in the combinatory therapy. NF-E2 p45-related factor 2, a member of the cap 'n\' collar family of transcription factors, is a key component of the antioxidant response element (ARE)-mediated induction of phase 2-detoxifying and antioxidant enzymes ([@bib31]). NF-E2 p45-related factor 2 is inactive in normal physiologic conditions because of its binding to the cytosolic protein Keap1. Redox stimulation causes activation of Nfr-2 and its consequent translocation to the nucleus, where it binds to ARE. Curcumin not only promotes inactivation of the Nrf2-Keap1 complex leading to increased Nrf-2 binding to AREs but it also stimulates HO-1 gene activity ([@bib11]; [@bib50]; [@bib45]). The Nrf2/ARE system is present both in healthy tissues, where it is involved in defence against chemical stress caused by potentially toxic compounds, and in cancer cells, where it accounts for the poor response to antitumor drugs ([@bib20]; [@bib51]). Increased Nrf-2 expression has been extensively studied in patients with several malignancies, including head and neck cancer ([@bib49]; [@bib22]). In these patients, Nrf-2 expression is significantly correlated with increased proliferation and treatment resistance to cisplatin, seemingly through the induction of antioxidant genes ([@bib56]). Cisplatin resistance is a major factor in disease relapse, and the Nrf-2 translocation inhibitory effect of curcumin as an adjuvant agent to cisplatin in our *in vitro* experiments appears pertinent to a tumour chemosensitisation effect. Similarly and consistent with the literature ([@bib30]; [@bib53]; [@bib13]), the cisplatin-induced redox-based modifications detected in our *in vivo* study of the organ of Corti determined the expression/activity of the transcription factor Nrf-2 and the consequent upregulation of the antioxidant defence system, HO-1. On the contrary, the cisplatin adverse effects in the cochlea were inhibited when curcumin was coadministered: hearing loss was decreased, apoptosis inhibited and Nrf-2 translocation and HO-1 labelling increased. This effect *in vivo* was present at the medium curcumin dose, whereas lower or higher doses were ineffective or detrimental, data consistent with a previous work and the potential hormetic activity of curcumin ([@bib6]; [@bib13]). Remarkably, in normal cells undergoing cisplatin insult, curcumin as an adjuvant to cisplatin increases Nrf-2 activation/translocation and its downstream transcription of antioxidant genes, providing thus protection against the oxidative stress. By contrast, in cancer cells curcumin combined to cisplatin inhibits Nrf-2 translocation, providing thus sensitisation to tumour oxidative stress. The different response to curcumin of cancer and normal cells during chemotherapy may depend on a combination of factors, including the metabolism of curcumin in those cells, baseline levels of stress and their capacities for mitigating oxidative stress as reported recently for a synthetic small molecule with cancer-selective antiproliferative and cytotoxic activity ([@bib43]).

Collectively, curcumin has demonstrated significant properties in the attenuation of all stages of tumour progression (survival, proliferation) and, by targeting pSTAT3 and Nrf-2 signalling pathways, provides chemosensitisation to cisplatin and protection from its adverse effects. In the perspective of a personalised approach of cancer therapy, the illustrated beneficial effects of curcumin as an adjuvant agent to cisplatin offer strong preliminary data for the justification of clinical studies in humans, possibly by using novel curcumin drug delivery systems.
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![**Curcumin influences PE/CA-PJ15 tumour progression and apoptosis.** (**A**--**D**) Graphs (mean±s.e.m.) showing percentage of cell survival (**A**) and tumour progression (**B**--**D**) at 24, 48 and 72 h after curcumin treatment. (**E**) Histogram showing the magnitude of tumour progression between 24 and 72 h, expressed as the percentage of the ratio of the number of cells counted at 72 and 24 h. \**P*\<0.05; \*\**P*\<0.001. (**F**--**J**) Representative images of DAPI-stained cells treated with curcumin: changes in morphology are indicated by arrows (swelling) and arrowheads (nuclear condensation and cellular fragmentation). Scale bar: 20 *μ*m. (**K**--**O**) Representative images of terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay in PE/CA-PJ15 treated with different curcumin doses. Arrows indicative of apoptotic cells. Scale bar: 50 *μ*m. (**P**) Western blot for Bax activation. Data are normalised to actin values. (**Q**) Bar graph shows the mean values (mean±s.e.m.) of apoptotic cells for each condition; \**P*\<0.05; \*\**P*\<0.001. Data are representative of three independent experiments; each count performed on 10 fields randomly selected for each experimental condition and each time point.](bjc2015359f1){#fig1}

![**Curcumin increases cisplatin effect in the combined administration.** (**A**--**D**) Graphs (mean±s.e.m.) showing percentage of cell survival (**A**) and proliferation (**B**--**D**) at 24, 48 and 72 h of incubation with cisplatin and curcumin at different doses. (**E**) Histogram shows the tumour progression between 24 and 72 h, expressed as a percentage of the ratio of the number of cells counted at 72 and 24 h. \**P*\<0.05, \*\**P*\<0.001 and \*\*\**P*\<0.0001. (**F**--**K**) Representative images of DAPI-stained cells; arrows and arrowheads indicate swelling and nuclear condensation/cellular fragmentation. Scale bar: 20 *μ*m. (**L**--**Q**) Terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay showing marked apoptotic-positive cells after cisplatin treatment (**M**) and after an adjuvant curcumin treatment (**N**--**Q**). (**R**) Related apoptotic cell count (mean±s.e.m.). \*\**P*\<0.001. Data are representative of three independent experiments; each count performed on 10 fields randomly selected for each experimental condition and each time point.](bjc2015359f2){#fig2}

![**Curcumin prevents pSTAT3 and Nrf2 nuclear translocation when administered in conjunction with CDDP.** (**A**--**J**) Representative immunofluorescence images of PE/CA-PJ15 treated with cisplatin and/or curcumin and double stained with DAPI (blue) and anti-pSTAT3 antibody (green). (**K**--**T**) Representative images of PE/CA-PJ15 cells labelled with Nrf-2 (red) and DAPI stained (blue). Scale bar: 20 *μ*m. (**U**--**V**) Histograms (mean±s.e.m.) showing optical density quantification in the nucleus and cytoplasm of treated cells for pSTAT3 and Nrf-2 labelling, respectively. \**P*\<0.05; \*\**P*\<0.001. Data are representative of three independent experiments; each quantification performed on 10 fields randomly selected for each experimental condition and each time point.](bjc2015359f3){#fig3}

![**Curcumin attenuates the functional and morphological damage induced by CDDP in the cochlea.** (**A** and **B**) Graphs show the threshold shift values in dB (mean±s.e.m.) in all experimental groups at day 3 (**A**) and day 5 (**B**) from treatment onset. (**C** and **D**) DPOAE amplitude measured at 16 kHz at days 3 and 5, respectively. (**E**--**H**) Representative surface preparations of the organ of Corti showing Rh-Ph staining. Asterisks indicate missing OHCs. (**I**) Cochleogram data (means±s.e.m.) show significant differences among groups in the middle and basal region of the cochlea at day 5. Data are representative of three independent experiments; *n*=5 animals per group. \**P*\<0.05; \*\**P*\<0.001.](bjc2015359f4){#fig4}

![**Curcumin potentiates Nrf2/HO-1 expression in the organ of Corti after CDDP treatment.** Representative images of high magnification of the organ of Corti double stained with DAPI (blue) and Nrf2 (red, left panel) or HO-1 (green fluorescence, right panel). Merged images are shown in A~3~--F~3~. XZ and YZ cross-sections in boxes (referred to the dashed lines) from the confocal Z-stack acquisitions show cytosolic or nuclear fluorescence signal (XZ and YZ boxes; a~1~, b~1~, c~1~, d~1~, e~1~, f~1~: DAPI staining; a~2~, c~2~, e~2~: Nrf-2 fluorescence; b~2~, d~2~, f~2~: HO-1 fluorescence; a~3~, b~3~, c~3~, d~3~, e~3~, f~3~: merge). Scale bar: 30 *μ*m. Data are representative of three independent experiments; *n*=5 animals per group.](bjc2015359f5){#fig5}

![**Curcumin enhances Nrf2/HO-1 activation in SGNs after CDDP treatment.** Representative images of high magnification of SGNs immunolabelled with Nrf2 (red fluorescence, left panel), HO-1 (green fluorescence, right panel) and double stained with DAPI (blue fluorescence). Merged images are shown in A~3~--F~3~. XZ and YZ cross-sections in boxes (referred to the dashed lines) from the confocal Z-stack acquisitions show cytosolic or nuclear fluorescence signal (XZ and YZ boxes; a~1~, b~1~, c~1~, d~1~, e~1~, f~1~: DAPI staining; a~2~, c~2~, e~2~: Nrf-2 fluorescence; b~2~, d~2~, f~2~: HO-1 fluorescence; a~3~, b~3~, c~3~, d~3~, e~3~, f~3~: merge). Scale bar: 20 *μ*m. Data are representative of three independent experiments; *n*=5 animals per group.](bjc2015359f6){#fig6}
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